Hilde Gerris Krol
PARTNERPhD Medical Biology
Good science failson bad systems
We reach clinical reality that is hard to get to. We use AI-driven extraction and synthesis across databases, and the signals are checked by specialists close to the field, so the picture stays deep and current in a landscape that keeps moving.
How we work
Rare disease experts
We work in rare disease, where clinical practice is hard to read from the published record alone. We use AI-assisted extraction and synthesis across the literature and our interview material, directed and checked by people with clinical and industry backgrounds.
Today we work through scoped research engagements, agreed around your question, your priority markets and the stakeholder groups that matter. Where you want the picture kept current, we agree updates as part of scope. Building a broader, continuously updated rare-disease intelligence base is our longer-term ambition, not something we sell as a subscription today.
That intelligence reaches clients through rare disease landscaping, TPP validation and barrier and driver analysis across European markets. Read how we measure ecosystem readiness or browse the client results from our KOL mapping and launch work.
Team
Built by people from rare disease.Designed for the AI era.
Our founding team pairs deep rare disease expertise with entrepreneurial execution and AI capability. Between us, we have worked across medical affairs, commercial strategy, scientific advisory, and AI-enabled innovation in metabolic disorders, neurological diseases, and oncology.
Jochem Bossenbroek
PARTNERMBA
Patrick de Boer
ADVISOR
Why Systemix?
Specialist research for the decision ahead.
Understand the evidence, involve the right experts and focus your next steps.
Rare disease is all we do.
Small populations, uncertain evidence, complex multidisciplinary care. We work in nothing else. 15+ rare disease landscapes and 500+ interviews with clinicians, payers and patients.
Verified by the people who shape the patient journey.
Databases count publications. We test every signal with the stakeholders who actually decide: treating clinicians, payers, diagnostic labs, reference centres and patient organisations, in each country. You see who leads the field and who decides, not who publishes most.
Europe, country by country.
Ten markets, including the ones most launch plans underestimate: Scandinavia, Austria and Central Europe. Treating centres, referral routes and access differ in every country. We map each one.
A living picture, delivered by senior partners.
AI-assisted monitoring tracks the field continuously. Senior partners validate it, interpret it and work with you directly. Deeper and faster than a manual study, and never out of date.
Consultancy for the decision in front of you. Living intelligence for everything after it.
INTELLIGENCE STARTING POINT
Consultancy
Rigorous rare disease landscaping, TPP validation, or barrier and driver analysis. Scoped tightly, validated with the stakeholders involved, and typically delivered weeks, not months.
- Rare disease landscaping (syndicated or tailored)
- TPP validation
- Barrier and driver analysis
Subscription
Living Intelligence
Ongoing, indication-specific intelligence on the disease ecosystem. We continuously monitor and refresh stakeholder perceptions, KOL and centre dynamics, patient pathways, competitors, payer signals and evidence, and tell you what the change means.
- Change alerts and sentiment analysis
- Scheduled intelligence updates
- Decision support when it counts
Auditable by design
Every number links back to its source. Every interpretation is clearly labelled. Confidence levels, evidence registers, version history, and cut-off dates are built in.
Bring us in early.
Tell us about the therapy, diagnostic, or disease area you want to bring to patients, and we'll show you what's possible.